Andy Serkis to Receive IBC’s Highest Award
30.7.2019 18:02:00 EEST | Business Wire | Press release
The IBC2019 International Honour for Excellence will go to Andy Serkis, the director, producer and actor who is today best known for his performance capture roles. These include Gollum, Supreme Leader Snoke, King Kong and Caesar in the Planet of the Apes series. Serkis will accept the award at the climax of the IBC2019 Awards Ceremony, on Sunday night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005738/en/
Andy Serkis (Photo: Business Wire)
“IBC is where the technology, the craft and the business of the media industry come together,” said Michael Crimp, CEO of IBC. “The International Honour for Excellence has a long history of rewarding those who have transformed our creative vision. Andy Serkis has achieved this by bringing extraordinary humanity to computer-generated characters.”
Serkis was born in England in 1964 and wanted to be an artist before becoming an actor, working in the theatre and on television. Today he is also a producer and director, with his London-based company Imaginarium Studios producing last year’s Mowgli, Legend of the Jungle, a new interpretation of Kipling’s originals adapted by Serkis, which also featured him co-starring as Baloo the bear alongside Christian Bale’s Bagheera.
His greatest achievement, though, is in making the shift from mere motion capture for CGI towards a combination of technology and the interpretive skill of the actor to create the fidelity of the performance in every detail. This is what gives the performance genuine humanity: his performance as Caesar in the three Planet of the Apes films won him an acting nomination from the Broadcast Film Critics Association.
For bringing together the highest performance standards with the latest in image recognition and CGI technology, the IBC2019 International Honour for Excellence will be presented to Andy Serkis.
“I feel incredibly honoured to have been chosen as the recipient of this year’s prestigious IBC award,” said Andy Serkis. “In turn, I must share this appreciation with the phenomenal legions of creative artists, visionaries and pioneers with whom I’ve been lucky enough to dance with on this journey of next generation storytelling.”
The IBC2019 Awards Ceremony is free to all IBC visitors. It takes place on Sunday evening 15 September at 18.30 in the RAI Auditorium, and will also see the presentation of two new awards this year, honouring achievements in social responsibility and a Young Pioneer, alongside the IBC Innovation Awards.
Earlier on Sunday Andy Serkis will feature in an IBC2019 Conference Convention Keynote , in conversation with Hollywood journalist Carolyn Giardina. They will review his career, the state of the art in motion capture, and discuss where he sees the future of technology in film and television. The Convention Keynote is at 12.30 in the Forum, and is free to attend.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005738/en/
Contact information
Aimee Moore
amoore@ibc.org
+44 (0) 20 7832 4104
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo
Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance and seamless integration into modern smart building, retail and industrial environments. Android 16 enables connected devices to communicate more inte
Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 10:00:00 EEST | Press release
Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo
Queue-it Announces Majority Investment from THL Partners18.8.2026 10:00:00 EEST | Press release
Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations & Data, which includes software companies that help organizations operate, secure, and optimize increasingly complex digita
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
